Among its many benefits for glaucoma, AI has the potential to help in screening, diagnosis, detection of progression, and prediction. A look at what it will take to move the field forward.
The abrupt closure of a drug manufacturer may lead to—and may have already led to—some drug shortages. Six experts look at the ripple effects in ophthalmology. (June EyeNet, published ahead of print.)
This supplement is designed to help ophthalmology practices navigate the rules of the “traditional” Merit-Based Incentive Payment System (MIPS).